Neurocrine Biosciences (NBIX) Stock Rating Upgraded by ValuEngine

Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

A number of other analysts also recently issued reports on NBIX. Canaccord Genuity assumed coverage on shares of Neurocrine Biosciences in a report on Wednesday, November 21st. They set a “buy” rating and a $111.00 price target for the company. Oppenheimer set a $105.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, January 29th. Robert W. Baird decreased their price target on shares of Neurocrine Biosciences from $131.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, December 13th. Needham & Company LLC set a $104.00 price objective on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $162.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, December 13th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $102.56.

NBIX stock opened at $84.83 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 8.24 and a current ratio of 8.36. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The stock has a market cap of $7.96 billion, a PE ratio of 385.59, a PEG ratio of 27.34 and a beta of 1.86.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, February 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.05. The business had revenue of $131.49 million for the quarter, compared to analyst estimates of $132.32 million. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.06%. The company’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.07 EPS. Sell-side analysts forecast that Neurocrine Biosciences will post 0.13 earnings per share for the current fiscal year.

In other Neurocrine Biosciences news, insider Eiry Roberts sold 1,857 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $84.09, for a total value of $156,155.13. Following the completion of the sale, the insider now directly owns 3,143 shares in the company, valued at $264,294.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 7,614 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total transaction of $671,250.24. Following the completion of the sale, the chief executive officer now owns 408,082 shares of the company’s stock, valued at $35,976,509.12. The disclosure for this sale can be found here. Insiders sold a total of 13,280 shares of company stock worth $1,163,054 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in Neurocrine Biosciences during the fourth quarter worth $32,000. Exane Derivatives lifted its position in Neurocrine Biosciences by 48,400.0% during the 4th quarter. Exane Derivatives now owns 485 shares of the company’s stock worth $35,000 after buying an additional 484 shares in the last quarter. Rehmann Capital Advisory Group lifted its position in Neurocrine Biosciences by 54.7% during the 3rd quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after buying an additional 197 shares in the last quarter. Penserra Capital Management LLC acquired a new position in Neurocrine Biosciences during the 4th quarter worth about $86,000. Finally, Arbor Wealth Management LLC bought a new stake in Neurocrine Biosciences during the 4th quarter worth about $92,000. 99.82% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Recommended Story: Day Trading – Risk Worth the Reward?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.